PANEL OF SERUM BIOMARKERS MAY PREDICT BENEFIT FROM BEVACIZUMAB (BEV) IN ADVANCED NSCLC PATIENTS

被引：0
|
作者：
Braun, Eduardo [1 ]
Fidler, Mary Jo [1 ]
Basu, Sanjib [1 ]
Gargaram, Anjali [2 ]
Walters, Kelly [2 ]
Fhied, Cristina [2 ]
Borgia, Jeffrey A. [2 ]
Bonomi, Philip D. [1 ]
机构：
[1] Rush Univ, Med Ctr, Div Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Div Biochem, Chicago, IL 60612 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S124 / S125
页数：2
相关论文
共 50 条
  • [41] Identifying factors to predict benefit from bevacizumab in progressive glioblastoma multiforme (GBM).
    Gleeson, Jack Patrick
    Alhusaini, Abdullah
    O'Halloran, Philip
    Harrold, Emily
    Keegan, Niamh M.
    Karadawi, Nabeeha Eltag
    Mammadov, Emin
    Kamel, Dalia
    Egan, Keith
    Molloy, Susan
    Hennessy, Bryan T.
    Breathnach, Oscar S.
    Grogan, William
    Morris, Patrick G.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients
    Eremo, Anna Gothlin
    Wegman, Pia
    Stal, Olle
    Nordenskjold, Bo
    Fornander, Tommy
    Wingren, Sten
    ONCOLOGY REPORTS, 2013, 29 (04) : 1467 - 1474
  • [43] Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
    Della Gravara, Luigi
    Battiloro, Ciro
    Letizia, Antonietta
    Cantile, Rosa
    D'Agnano, Vito
    Sica, Giacomo
    Rocco, Danilo
    JOURNAL OF MOLECULAR PATHOLOGY, 2021, 2 (02): : 197 - 206
  • [44] Reduced benefit of bevacizumab in patients with advanced colorectal cancer who continue to smoke
    Imbevaro, S.
    Rescigno, P.
    Mazurek, M.
    Jirillo, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S517 - S518
  • [45] Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study
    Marmorino, Federica
    Cremolini, Chiara
    Loupakis, Fotios
    Barbara, Cecilia
    Dargenio, Francesco
    Miraglio, Emanuela
    Masi, Gianluca
    Salvatore, Lisa
    Marcucci, Lorenzo
    Antonuzzo, Lorenzo
    Chiara, Silvana
    Banzi, Chiara
    Schirripa, Marta
    Amoroso, Domenico
    Bonetti, Andrea
    Martignetti, Angelo
    Paris, Myriam
    Boni, Luca
    Tomcikova, Daniela
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
    Marmorino, F.
    Cremolini, C.
    Loupakis, F.
    Salvatore, L.
    Masi, G.
    Barbara, C.
    Dargenio, F.
    Miraglio, E.
    Ginocchi, L.
    Antonuzzo, L.
    Moretto, R.
    Schirripa, M.
    Chiara, S.
    Banzi, C.
    Amoroso, D.
    Bonetti, A.
    Martignetti, A.
    Paris, M.
    Boni, L.
    Tomcikova, D.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
    Marmorino, F.
    Cremolini, C.
    Loupakis, F.
    Antoniotti, C.
    Barbara, C.
    Dargenio, F.
    Miraglio, E.
    Masi, G.
    Salvatore, L.
    Schirripa, M.
    Borelli, B.
    Marcucci, L.
    Antonuzzo, L.
    Chiara, S.
    Banzi, C.
    Amoroso, D.
    Bonetti, A.
    Martignetti, A.
    Paris, M.
    Boni, L.
    Tomcikova, D.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27 : 103 - 103
  • [48] Low incidence of grade 3 bleeding events and low discontinuation rates associated with first-line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study
    Tsai, C.
    Griesinger, F.
    Laskin, J.
    Crino, L.
    Pavlakis, N.
    Dansin, E.
    Thatcher, N.
    Ko, Y. D.
    Metzger, J.
    Garrido, P.
    EJC SUPPLEMENTS, 2009, 7 (02): : 557 - 558
  • [49] Plasma concentrations of pemetrexed to predict clinical outcomes in patients with advanced NSCLC
    Visser, S.
    Koolen, S.
    de Bruijn, P.
    Mathijssen, R.
    Stricker, B.
    Aerts, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S76 - S77
  • [50] Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatinpaclitaxel (CP) ± bevacizumab (BEV). Results from GOG-0218.
    Secord, Angeles Alvarez
    Tritchler, David
    Liu, Yingmiao
    Starr, Mark D.
    Brady, John C.
    Lankes, Heather A.
    Hurwitz, Herbert
    Mannel, Robert S.
    Tewari, Krishnansu Sujata
    O'Malley, David M.
    Gray, Heidi J.
    Bakkum-Gamez, Jamie Nadine
    Fujiwara, Keiichi
    Boente, Matthew
    Deng, Wei
    Burger, Robert Allen
    Birrer, Michael J.
    Nixon, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345